Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Sponsor: Yale University
Summary
The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (AI-Echo) to identify transthyretin amyloid cardiomyopathy (ATTR-CM) in adults with heart failure. Model performance will be validated through comparison with technetium-99m pyrophosphate (PYP) imaging results.
Official title: Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM): TRACE-AI Prospective Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2026-03
Completion Date
2026-12
Last Updated
2026-02-10
Healthy Volunteers
No
Interventions
ATTR-CM AI-ECG and AI-Echo Model
AI-based sequential screening approach for ATTR-CM
Locations (1)
Yale New Haven Health System
New Haven, Connecticut, United States